Silmitasertib

DRUG3 trials

Sponsors

Senhwa Biosciences, Inc., University of Arizona, Milton S. Hershey Medical Center

Conditions

CoronavirusCovid19Ewing SarcomaLiposarcomaNeuroblastomaOsteosarcomaRhabdomyosarcoma

Phase 1

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

RecruitingNCT06541262

Milton S. Hershey Medical CenterEwing Sarcoma, Liposarcoma, Neuroblastoma +2

Start: 2024-10-30End: 2035-11-01Target: 104Updated: 2026-09-03

Phase 2

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

CompletedNCT04663737

Senhwa Biosciences, Inc.Covid19

Start: 2020-11-30End: 2021-10-04Updated: 2025-01-16

Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)

TerminatedNCT04668209

University of ArizonaCoronavirus

Start: 2021-01-21End: 2022-10-19Updated: 2023-11-07

Related Papers

Abstract CT271: Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors

Cancer Research2026-04-17

Abstract 3065: Therapeutic efficacy of CK2 inhibitor in patient-derived lung metastatic model of Ewing sarcoma

Cancer Research2026-04-03

Abstract 3016: Therapeutic efficacy of a novel combination of ck2 inhibitor cx-4945 with cytotoxic therapy in neuroblastoma preclinical models

Cancer Research2025-04-21

Abstract 6916: CK2 inhibitor shows anti-tumor activity in Ewing sarcoma preclinical models

Cancer Research2025-04-21